Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert K. who wrote (16766)	4/8/2004 1:13:14 AM
From: Bluegreen	Respond to of 17367

Remember FOLKS.......Raptiva..........the LIGHT TOUCH!!!!!!!!!!!!!!! Look at the Heavy Handed Enbrel search results>>>>>>>http://www.druginjurylaw.com/Enbrel-lawsuits.html

To: Robert K. who wrote (16766)	4/8/2004 11:50:23 AM
From: Bluegreen	Respond to of 17367

Bob, just think if Raptiva was basic cable subscriptions. Let's do the numbers. Just rough numbers just so you get the idea.........2 million dollars a month divided by 14 dollars a month for basic cable......that equals around 143,000 subscribers JUST THE FIRST FULL QUARTER!!!!!!!!!!! People forget that Avastin IS NOT like this. With Avastin you get the money right away before the patient passes away and book the revenue in a very short period of time. Raptiva is a product like LONG TERM, VERY LONG TERM, POSSIBLY for the rest of the patient's life JUST LIKE your cable bill. This is VERY exciting to watch.........JUST LIKE DAILY COMPOUNDING INTEREST OR RAPIDLY VERY RAPIDLY SIGNING UP CABLE SUBSCRIBERS!!!!! AND........biologics have a HUGE profit margin!!!!! Double AND........think IF we get European approval!!!!!!!!!!!!